Alligator Bioscience sells mitazalimab rights to Biossil for $0.75 million upfront
Swedish biotech Alligator Bioscience agreed to sell all assets tied to its mitazalimab antibody to Biossil, with milestones up to $108 million. TradingView reported the deal.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Swedish biotech Alligator Bioscience (Nasdaq Stockholm: ATORX) has signed a deal to transfer all rights and assets tied to its CD40 agonist antibody mitazalimab to Biossil Inc., according to TradingView. Alligator will receive an upfront payment of USD 0.75 million and may collect up to USD 108 million in milestones, plus royalties on future sales.
Once the deal closes, Biossil will take over development, manufacturing and patent costs. Closing is expected within 30 days of signing. The company says the sale fits its strategy of focusing on its economic interest in HLX22 and removes the cost of maintaining the mitazalimab program. Most of the payments depend on future events, and the company gives no assurance they will be received.
why it matters
The deal is small for a listed company and does not affect broader markets. It matters mainly to Alligator's shareholders, who would see lower running costs and a clearer focus on HLX22, while larger payouts depend on later regulatory approvals and sales.
tags
instruments
sources
- Alligator Bioscience signs agreement to sell mitazalimab to Biossil — TradingView, 31 October 2026 at 07:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗